Patients
PD, hepatitis
HEPATITIS B, DISEASE, HEPATITIS, ONCOLOGY
Between March 3, 2020, and December 15, 2020, 139 patients, including 11 subjects who had positive genetic results in the third‐party commercial reports and 10 other subjects who had detectable Trial profile. As of the data cutoff date of January 29, 2021, eight patients discontinued treatment, with PD being the most common reason, and 23 patients were still receiving treatment. The median duration of treatment was 3.8 months (range, 1.5–7.4). The median duration of follow‐up was 5.1 months (range, 1.5–9.3) in the EEP/PPS.Of 31 patients enrolled, most were female (67.7%), the median age was 56 years, and most had a diagnosis of ICC (96.8%) and stage IV disease (90.3%). Fifteen (48.4%) patients had a history of hepatitis, and 22 (71.0%) had a positive test for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb; Table Patient baseline characteristics
Abbreviation: ECOG, Eastern Cooperative Oncology Group.